330794-35-9

Usage

Uses

Used in Organic Synthesis:
4-((N-BOC-AMINO)METHYL)PHENYLBORONIC ACID PINACOL ESTER is used as a reagent for the formation of carbon-carbon and carbon-heteroatom bonds in organic synthesis. Its ability to facilitate the formation of these bonds makes it a valuable tool in the creation of complex organic molecules.
Used in Medicinal Chemistry:
In the field of medicinal chemistry, 4-((N-BOC-AMINO)METHYL)PHENYLBORONIC ACID PINACOL ESTER is used as a building block for the synthesis of pharmaceuticals and bioactive molecules. Its unique structure and functional groups allow for the development of new compounds with potential therapeutic applications.
Used in Drug Development:
4-((N-BOC-AMINO)METHYL)PHENYLBORONIC ACID PINACOL ESTER is used in drug development as a key intermediate in the synthesis of various drug candidates. Its versatility and reactivity in organic reactions enable the creation of novel compounds with potential therapeutic effects.
Used in Chemical Research:
In the realm of chemical research, 4-((N-BOC-AMINO)METHYL)PHENYLBORONIC ACID PINACOL ESTER is used as a subject of study to explore new reaction pathways, mechanisms, and applications. Its unique properties and reactivity provide opportunities for advancing the understanding of organic chemistry and the development of new synthetic strategies.

InChI:InChI=1/C18H28BNO4/c1-16(2,3)22-15(21)20-12-13-8-10-14(11-9-13)19-23-17(4,5)18(6,7)24-19/h8-11H,12H2,1-7H3,(H,20,21)

Upstream product

• 68819-84-1 tert-butyl N-(4-bromobenzyl)carbamate 
• 73183-34-3 bis(pinacol)diborane 
• 24424-99-5 di-tert-butyl dicarbonate 
• 138500-88-6 (4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)methanamine 
• 68837-59-2 4-bromo-2-methylbenzoic acid 
• 877131-77-6 2-(4-bromo-2-ethylbenzyl)isoindoline-1,3-dione 
• 877131-21-0 (4-bromo-2-ethylphenyl)methanol 
• 644984-78-1 4-bromo-2-ethylbenzoic acid 
• 3959-07-7 4-Bromobenzylamine 
• 861359-74-2 diisopropylethyl amine 
• 26177-44-6 4-bromobenzylamine hydrochloride 

Downstream Products

• 950201-66-8 C₂₃H₂₉N₃O₃ 
• 1313439-63-2 6-(4-(aminomethyl)phenyl)-1-methyl-7-phenyl-1H-pyrido[2,3-b][1,4]oxazin-2(3H)-one 
• 1313441-64-3 tert-butyl 4-(2-oxo-7-phenyl-2,3-dihydro-1H-pyrido[2,3-b][1,4]oxazin-6-yl)benzylcarbamate 
• 1289179-33-4 3-[4-(3-amino-1Η-pyrazolo[3,4-b]pyridin-5-yl)-benzylamino]-6-cyano-pyrazine-2-carboxylic acid [1-(3,4-difluoro-phenyl)-ethyl]-amide 
• 138500-88-6 (4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)methanamine 
• 1403255-57-1 4'-(aminomethyl)-N-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-5-(ethyl(tetrahydro-2H-pyran-4-yl)amino)-4-methyl-[1,1'-biphenyl]-3-carboxamide 
• 950201-67-9 C₃₀H₃₄FN₃O₃ 

Relevant academic research and scientific papers

COMPOUNDS AND USES THEREOF

The present disclosure features compounds useful for the treatment of BAF complex-related disorders.

Compound targeting to I-type PRMT and preparation method and application of compound

The invention relates to the technical field of chemical drugs, in particular to a compound targeting to I-type PRMT, and a preparation method and application thereof. The compound A and a pharmaceutically acceptable salt thereof belong to covalent inhibi

N-benzylpiperidinol derivatives as novel USP7 inhibitors: Structure–activity relationships and X-ray crystallographic studies

USP7 as a deubiquitinase plays important roles in regulating the stability of some oncoproteins including MDM2 and DNMT1, and thus represents a potential anticancer target. Through comparative analysis of USP7 co-crystal structures in complex with the rep

Discovery of BIIB068: A Selective, Potent, Reversible Bruton's Tyrosine Kinase Inhibitor as an Orally Efficacious Agent for Autoimmune Diseases

Autoreactive B cell-derived antibodies form immune complexes that likely play a pathogenic role in autoimmune diseases. In systemic lupus erythematosus (SLE), these antibodies bind Fc receptors on myeloid cells and induce proinflammatory cytokine producti

Diketopyrrolopyrrole derivative and application thereof

The invention provides a diketopyrrolopyrrole derivative and application thereof as well as relates to a diketopyrrolopyrrole derivative. The structural formula of the diketopyrrolopyrrole derivativeis as shown in a formula (I): the formula (I) is as shown in the description; in the formula (I), R1 is selected from a group as shown in a formula (I-a), a formula (I-b), a formula (I-c), a formula (I-d) or a formula (I-e) (the formulas are as shown in the description); and in the formula (I-a), the formula (I-b), the formula (I-c), the formula (I-d) and the formula (I-e), * shows connection position. The diketopyrrolopyrrole derivative has excellent photoelectric property and can be applied in the field of organic photoelectric functional devices.

BIARYL COMPOUNDS USEFUL FOR THE TREATMENT OF HUMAN DISEASES IN ONCOLOGY, NEUROLOGY AND IMMUNOLOGY

The present invention provides compounds and compositions thereof which are useful as inhibitors of Bruton's tyrosine kinase and which exhibit desirable characteristics for the same.

Controlled synthesis of a novel heteropolymetallic complex with selectively incorporated lanthanide(III) ions

A novel synthetic strategy toward a heteropolymetallic lanthanide complex with selectively incorporated gadolinium and europium ions is outlined. Luminescence and relaxometric measurements suggest possible applications in bimodal (magnetic resonance/optic

An accessible bicyclic architecture for synthetic lectins

Bicyclic carbohydrate receptors are easier to synthesise than tri- or tetra-cyclic relatives, and are better adapted to bind monosaccharide residues with bulky appendages. Disaccharides containing β-glucosyl units are preferred substrates.

Conductance switching and mechanisms in single-molecule junctions

A molecular switch: The conductance of a new molecular device based on graphene-molecule junctions was reproducibly switched between open and closed states under irradiation of external light (see picture). Three photochromic diarylethene derivatives with different substituents were used as key elements of the molecular devices. Copyright

Purinenucleoside derivative modified in 8-position and medical use thereof

The present invention provides an 8-modified purinenucleoside derivative which is useful for diseases associated with an abnormality of plasma uric acid level. An 8-modified purinenucleoside derivative represented by the following formula (I), a prodrug thereof or a pharmaceutically acceptable salt thereof, or a hydrate or solvate thereof, is useful for the prevention or treatment of gout, hyperuricemia, urinary lithiasis, hyperuricemic nephropathy or the like. In the formula, n is 1 or 2; RA is a hydrogen atom or a hydroxyl group; R1 is a hydrogen atom, a hydroxyl group, a thiol group, an amino group or a chlorine atom; ring J represents an optionally substituted 2-naphthyl group, or a group represented by the following general formula (II) wherein Y represents a single bond or a connecting group; ring Z represents an optionally substituted aryl group or heteroaryl group or the like; and R2 to R4, P1 and Q represents a halogen atom, a cyano group or the like.